Novo Nordisk A/S $NVO Shares Acquired by Matauro LLC

Matauro LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 50.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,076 shares of the company’s stock after purchasing an additional 15,739 shares during the quarter. Matauro LLC’s holdings in Novo Nordisk A/S were worth $2,612,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. First Hawaiian Bank raised its stake in Novo Nordisk A/S by 0.6% in the first quarter. First Hawaiian Bank now owns 22,401 shares of the company’s stock valued at $1,556,000 after buying an additional 142 shares during the last quarter. Anchor Investment Management LLC increased its holdings in shares of Novo Nordisk A/S by 1.1% during the first quarter. Anchor Investment Management LLC now owns 13,597 shares of the company’s stock valued at $944,000 after acquiring an additional 150 shares in the last quarter. Werba Rubin Papier Wealth Management raised its position in shares of Novo Nordisk A/S by 4.1% in the 2nd quarter. Werba Rubin Papier Wealth Management now owns 4,378 shares of the company’s stock valued at $302,000 after purchasing an additional 173 shares during the last quarter. Atwood & Palmer Inc. boosted its stake in Novo Nordisk A/S by 31.8% in the 2nd quarter. Atwood & Palmer Inc. now owns 737 shares of the company’s stock worth $51,000 after purchasing an additional 178 shares in the last quarter. Finally, Beacon Financial Group grew its position in Novo Nordisk A/S by 4.3% during the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock worth $239,000 after purchasing an additional 178 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NVO. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating for the company in a report on Tuesday, November 25th. Hsbc Global Res lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Morgan Stanley reissued an “underweight” rating and issued a $42.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Finally, Rothschild & Co Redburn upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have issued a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average price target of $53.33.

Novo Nordisk A/S Stock Up 1.0%

Shares of NVO opened at $48.10 on Friday. The company has a market capitalization of $214.76 billion, a price-to-earnings ratio of 13.98 and a beta of 0.67. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The stock’s 50-day moving average price is $49.84 and its 200-day moving average price is $57.69. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The company had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo filed an NDA with the U.S. FDA for once‑weekly CagriSema, a next‑generation combination obesity injection that showed superior Phase III weight‑loss results — a potential major booster to its obesity franchise if approved. Article Title
• Positive Sentiment: Novo is pursuing a higher 7.2 mg Wegovy dose after data showed stronger weight loss — this could help reclaim share versus rivals (e.g., Eli Lilly’s Zepbound) if approved and commercialized effectively. Article Title
• Positive Sentiment: Analyst/commentary pieces highlight upside from oral Wegovy development, supply‑chain fixes and restructuring that could materially improve margins and growth if execution continues. Article Title
• Positive Sentiment: Kepler Capital initiated/maintained a buy view (reported coverage), giving some buy‑side support to the shares. Article Title
• Neutral Sentiment: UBS reiterated a Neutral (Hold) rating and left its price target unchanged, signaling continued caution on competitive pressures despite product progress. Article Title
• Neutral Sentiment: Commentary pieces are reassessing Novo’s valuation after a steep, year‑long share decline; some see a longer runway to recovery while others point to durable competitive threats. Article Title
• Negative Sentiment: Novo issued profit warnings and underwent a CEO change earlier this year and cut guidance, contributing to a large YTD share decline; that operational uncertainty remains a drag on investor confidence. Article Title
• Negative Sentiment: Shares recently dipped more than the broader market after earnings/profitability concerns were flagged; short‑term volatility is likely to persist as investors weigh approvals vs competitive share losses. Article Title

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.